Background. Survival curves following surgical treatment of cutaneous melanoma are heavily influenced by early deaths. Therefore, survival estimates may be misleading for long-term cancer survivors. We examined whether conditional survival (CS) is more accurate in predicting long-term melanoma survival. Methods. We used the Surveillance, Epidemiology, and End Results database (1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005) to identify patients who underwent surgical treatment for melanoma. We included patients with T2-T4 disease and with known nodal status. Patients were stratified into low-risk (T2-3N0M0) and high-risk (T4N0M0 or T2-4N1-3M0) categories. We defined CS as time-specific estimates conditioned on living to a certain point in follow-up, and calculated 10-year cancer-specific survival curves conditioned on annual survival. We adjusted for potential confounders using a Cox proportional hazards regression model (a = 0.05). Results. A total of 8647 patients met inclusion criteria (low-risk, 5987 [69.2%]; high-risk, 2660 [30.8%]). At diagnosis, low-risk patients had a significantly better 10-year survival rate (low-risk, 79.6%; high-risk, 41.2%; P \ 0.001). On CS analysis, survival differences remained until 8 years after treatment, after which 10-year cancerspecific survival rates were no longer significantly different (P = 0.51) for low-risk (95.4%) and high-risk (91.7%) groups. Multivariate analysis demonstrated that age, gender, location, and ulceration (initial predictors of survival) were no longer predictive after 8 years of survival. Conclusions. For patients who survive 8 years after surgical treatment of melanoma, CS data become discordant with traditionally used estimates. Our findings have important implications for patient counseling, as high-risk melanoma survivors may require no more intensive surveillance than low-risk survivors 8 years after treatment.
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For patients with cutaneous melanoma C1 mm in thickness, adequate local treatment includes wide local excision (WLE) and sentinel lymph node (LN) evaluation. [1] [2] [3] Following local treatment, several tumor-and patient-related characteristics affect prognosis. Tumor ulceration and thickness, anatomic location of primary tumor, patient age and gender, and lymph node metastasis are known to affect cancer survival. 4 Specifically, lymph node metastases present at the time of original diagnosis are a powerful predictor of patient survival. 1, [5] [6] [7] These prognostic characteristics define our current understanding of cancer-specific survival (CSS) and provide the basis for patient counseling and long-term decision-making. Because CSS rates are heavily influenced by early cancer deaths, traditional estimates based on early prognostic factors may not accurately predict long-term outcomes among melanoma survivors.
An alternative approach for understanding long-term cancer-specific outcomes may be through the use of conditional survival (CS). CS calculates the changing risk of cancer death over time and provides estimates of on-going survival given the precondition of having already survived to a certain point after initial treatment. Because CS data are not influenced by early cancer deaths, CS analysis may be a more accurate estimate of long-term CSS and may be a more important factor in determining appropriate surveillance and screening for melanoma survivors. [8] [9] [10] [11] [12] [13] The objective of this investigation was to determine if, at some point in follow-up, the likelihood of future survival is no longer impacted by prognostic factors that were significant predictors of survival at the time of diagnosis. It was our hypothesis that, after a certain accumulated CSS time, patient and tumor characteristics present at the time of diagnosis would no longer be significant predictors of outcomes for patients with local and regional melanoma following adequate local treatment.
PATIENTS AND METHODS

Definition of Conditional Survival
The statistical methods for determining CS have been previously described. 8 In summary, CS is a function of the traditional survival estimates, adjusted to reflect the probability of survival conditioned on living to a certain point in follow-up.
Data Sources
The Surveillance, Epidemiology, and End Results (SEER) database is a well-established, population-based set of cancer registries encompassing 26% of the U.S. population as of 2000.
14 SEER has been widely validated, and details of use are well described. 8, 11, 13 In this study we used the November 2007 submission database (which provides data from 1973 through December 31, 2005). Because of the negative impact of Hurricane Katrina on data collection, we excluded data collected by the Louisiana cancer registry in 2005.
Study Cohort
Using the SEER database, we selected patients who underwent WLE of T2-T4 cutaneous melanomas with histological evaluation of regional lymph nodes and were diagnosed in 1992 or later. Because of their uniformly high survival rates and because melanoma tumors \1 mm in thickness do not routinely undergo lymph node evaluation, patients with T1 tumors were excluded from our analysis.
Though SEER registries began collecting LN data in 1988, clinically negative regional lymph nodes were not routinely assessed until the seminal studies on sentinel lymph node evaluation were published. 1, 5, 7 Therefore, we limited our data collection to the years 1992 through 2005.
We included patients with the following International Classification Disease for Oncology, 3rd Edition (ICD-O3) We excluded patients with unknown T-stage or nodal status, nonmelanoma skin cancer, systemic metastases, unknown primary melanoma site, or a second primary (nonmelanoma) cancer diagnosis. Patients were also excluded if their disease was diagnosed at autopsy or by death certificate only. Non-Caucasian populations were excluded because of their limited numbers and disproportional incidence of advanced disease and poor outcomes. 4, 11, 15 Finally, we excluded patients under the age of 18. The remaining 8647 patients were then stratified as follows: low-risk (T2-3N0) and high-risk (T4N0 or T2-4N1-3).
Statistical Analyses
Data were analyzed using SAS version 9.1 (SAS Institute, Cary, NC). For all statistical testing, we used a twosided significance level of 0.05. Conditional survival was defined as time-specific estimates conditioned on surviving to a certain point in follow-up. We calculated 10-year cancer-specific survival rates using the Kaplan-Meier method for low-risk vs high-risk patients at the time of diagnosis. We then calculated 10-year cancer-specific relative conditional survival rates for all melanoma survivors 1 year after surgical treatment and for every year of cumulative survival thereafter. Using the log-rank method, we tested for survival rate significance between low-and high-risk groups at time zero (defined as the time of diagnosis) and for each year of cumulative CS thereafter, until the curves converged.
We adjusted for potential confounding covariates (age, gender, location of primary tumor, and presence or absence of ulceration) using Cox proportional hazards regression models.
The Human Subjects Committee at the University of Minnesota deemed that this study was exempt from formal review by the Institutional Review Board.
RESULTS
A total of 8647 patients met the inclusion criteria during the specified time (Table 1) . Using the definition outlined above, 5987 patients (69.2%) were placed into the low-risk category (T2-T3, N0) and 2660 patients (30.8%) into the high-risk category (T4N0 or T2-4N1-3). Patient and tumor characteristics presented by risk category at time of diagnosis are presented in Table 2 . Nearly half of the patients were between the ages of 40 and 60 years old in the combined cohort (n = 3731, 43.1%). This remained true when separated by risk group; low-risk patients were not younger than high-risk patients, with the majority of patients in each group falling between the ages of 40 and 60 (43.7 and 42.0%, respectively). Male gender was predominant.
Tumor characteristics varied somewhat across groups; extremity was the most common primary tumor site overall (n = 4181, 48.4%), followed by trunk (n = 2936, 33.9%) and head and neck (n = 1530, 17.7%). When categorized by risk, 50.1% of low-risk patients and 44.5% of high-risk patients had extremity tumors; high-risk patients had slightly more primary trunk tumors (37.8%) than low-risk patients (32.2%). In all patients, ulceration was uncommon (n = 1482, 17.1%), although it was more prevalent in the high-risk group (n = 677, 25.5%).
At diagnosis (Time 0), low-risk patients had a significantly better 10-year CSS rates (low-risk, 79.6%; high-risk, 41.2%; P \ 0.001). Analysis of 10-year CSS rates conditioned on annual cumulative survival remained significantly different between low-and high-risk groups after 1, 2, 3, 4, 5, 6, and 7 years of CS; after 5 years of CSS, low-risk patients (n = 2247) still have a higher likelihood of 10-year survival (91.3%) when compared with high-risk (n = 651, 84.1%, P \ 0.001). This difference held until 8 years after local treatment; at that point, CS rates were no longer significantly different between low-risk (n = 1472) and high-risk (n = 373) groups (lowrisk, 95.4%; high-risk, 91.7%; P = .51) (Fig. 1a-c) .
Heterogeneity testing demonstrated a significant interaction between LN status and presence of ulceration; however, this interaction was not clinically relevant. When stratified by ulceration status, the survival data for low-and high-risk tumors still converge and lose significance after 8 years of cancer-specific survival. Table 3 lists hazard ratio (HR) and 95% confidence intervals (CIs) for tumor and patient characteristics stratified by survival time. Multivariate analysis demonstrated that high-risk tumors, ulcerated tumors, trunk tumors, head and neck tumors, male gender, and age [60 at the time of diagnosis adversely affected 10-year CSS. These factors began to lose significance after 5 years of CSS; at this time, only high-risk tumors (HR 2.2, 95% CI 1.6-3.0) and head and neck primary tumors sites (HR 1.6, 95% CI 1.1-2.5) were significant. Notably, ulceration (an important prognostic factor at the time of diagnosis), lost significance after 5 years of survival. After 8 years of cumulative CSS, all of the early risk factors were no longer significant predictors of future cancer-specific outcome.
DISCUSSION
The utility of CS as a means of stratifying risk and survival after a certain cancer-free period is becoming increasingly established; such information has the potential to significantly impact patient counseling and decisionmaking. 8, 9, 11, 12, 16 In the current study evaluating more than 8700 patients, we demonstrate that melanoma conditional survival data may be a more appropriate tool for understanding on-going survival for patients who survive the initial period following WLE. Our analysis demonstrates that traditional American Joint Committee on Cancer rates are heavily influenced by early death; as such, traditional survival data may not be the most accurate predictor for long-term melanoma survivors. 17 Although the current understanding is that LN status is the greatest predictor of cancer survival, our analysis demonstrates that among patients who survive the first 8 years after treatment, LN status is no longer a significant predictor of on-going survival; these findings may have important implications for the counseling of long-term melanoma survivors. 5, 7, 18, 19 Currently, the National Comprehensive Cancer Network (NCCN) guidelines recommend WLE with 1-cm margins for thin melanoma (\1 mm in thickness) and 2-cm margins for tumors C1 mm. 2 In a 2003 meta-analysis representing more than 2000 patients, Haigh and colleagues found that surgical excision margins beyond 2 cm conferred no significant survival benefit. 20 For tumors C1 mm, sentinel lymph node biopsy (SLNB) is recommended for patients with clinically negative nodes. 1, 5, 7 In the Multicenter Selective Lymphadenectomy Trial (MSLT) Morton and colleagues reported a significant 5-year survival benefit for patients undergoing SLNB (72.3%) versus those managed with delayed completion node dissection if metastatic disease became clinically detectable (52.4%). 21 For thin tumors \ 1 mm (T1), NCCN guidelines recommend consideration of SLNB if ''adverse features'' (ulceration, positive deep margin, lymphovascular invasion, or mitotic rate [ 1 per mm 2 ) are present; however, the survival benefit of SLNB to this population of patients remains unclear. 2 In the current study, 43,441 patients were identified with T1 tumors; of those, 16.8% underwent LN evaluation and 13% of those were positive, resulting in an overall upstaging of less than 2%. Because patients with T1 tumors have an overall 10-year CSS of 90%, and because LN evaluation is a discretionary part of their management, they were excluded.
In agreement with our findings, several studies have demonstrated that the risk of cancer-specific death changes over time. Gamel and colleagues published a series of more than 5800 melanoma patients in 2002, demonstrating that after 15 years of cancer-specific survival, the probability of on-going survival was equal among all risk groups. 4 Similarly, Slingluff and colleagues reported that after 10 years of survival, the risk of melanoma death in early-stage disease was nearly eliminated. 22 In our direct comparison of melanoma conditional survival rates, we demonstrated that traditional survival curves are too heavily impacted by early death, causing an initial steep drop. When this initial steep drop stabilizes, CS rates provide more accurate estimates of long-term survival and are based on the premise that as survival time increases, the likelihood of further survival increases. [10] [11] [12] 16 Clearly, after a certain period of cancer-free survival, patient prognosis is actually better than what would have been predicted at the time of diagnosis. Our data support this finding in a novel and direct comparison of CSS among low-and high-risk melanoma categories, with the finding that high-risk melanoma is no longer a significant prognostic indicator after 8 years of CSS.
Similarly, we demonstrated that gender, age, anatomic location, and ulceration status of the primary tumor were not predictive of CSS after 8 years of cumulative survival, despite the finding that these factors were significant predictors of survival prior to that time. 4, [23] [24] [25] [26] This observation suggests that cumulative survival time is the greatest predictor of future survival for long-term melanoma survivors after adequate melanoma treatment.
We acknowledge several limitations to our analysis. For uniformity, we focused on those patients with documented LN staging, excluding more than 7500 patients without nodal status documented. Thus, our cohort is limited to those patients who received care consistent with established treatment guidelines. Erickson Foster and colleagues estimated that nearly 20% of patients are undertreated based on current NCCN guidelines; regional variations in adherence to guidelines may interfere with any population-based survival analysis. 3 Similarly, SEER does not record the use of adjuvant systemic therapies, such as interferon-alpha. Thus, we cannot analyze the impact, if any, that such adjuvant therapies may have on CS.
Despite the potential limitations, SEER is populationbased and includes patients from diverse locations and practices in the United States, making our findings broadly reflective of standard practice. Moreover, our populationbased study includes large numbers of patients with longterm follow-up.
In conclusion, this is the first analysis that directly compares survival rates between low-risk and high-risk patients and demonstrates that after 8 years of melanoma survival, CS data become discordant with traditionally used estimates. As an alternative to traditional estimates, CS data provide a more accurate understanding of patients' changing risk of cancer death over time, resulting in meaningful implications for patient surveillance and follow-up. The results of this study suggest that after a certain point in follow-up, prognostic factors present at the time of diagnosis are no longer significant predictors of on-going survival; as such, patients who initially present with high-risk tumors may require no more aggressive surveillance than their low-risk counterparts after 8 years of survival. Alternatively, ongoing surveillance may potentially be standardized, focusing on clinical skin and lymph node evaluation for all melanoma survivors. The elimination of routine and potentially unnecessary imaging studies has important implications for resource utilization, a timely finding given the current medical economy. For all patients at time of diagnosis, at 5 years of conditional survival, and at 8 years of conditional survival CI confidence interval * P \ 0.05
